Table 1.

Results of ppatient tumor flow cytometry analysis

Pt no	Anti PD-1 resistance	Total no Prior therapies/ prior anti-PD-1/prior anti CTLA-4	CD3+Pre	CD3+Post	% change CD3+	CD8+ Pre	CD8+ Post	% change CD8+	CD4+ Pre	CD4+ Post	% change CD4+	Current Status
1	Primary	1/yes/no	11 225	10 996	−2	3274	4419	35	2907	2414	−17	Anti-CTLA-4 plus anti-PD1, alive 3.2 years
2	Primary	3/yes/yes	799	903	+13	324	389	17	152	176	16	Died 23 months
6	Primary	3/yes/yes	725			211			199			Died 11 months
3	Inadequate	2/yes/yes	18 923			5237			5647			Died 20 months
4	Secondary	>10/yes/yes	13 932	9452	−32	8771	4525	−48	2304	1999	−13	Died 19 months
5	Secondary	4/yes/no	8980	31 697	252	1760	7968	352	3033	10 228	237	Anti-PD-1, progressed 25 months, alive 2.7 years
7	Secondary	2/yes/yes	10 557	55 708	428	5054	24 712	389	1642	9772	495	Died 9 months
10	Secondary	1/yes/yes										Died 13 months
8	Primary *	Yes/no	86 395	148 957	72	52 799	89 906	70	12 387	28 254	128	Anti-PD-1, alive 2.5 years
9	Primary*	Yes/no	22 376			14 061			2681			Anti-PD-1 alive 2.5 years
11	Secondary	Yes/no		142 502			13 075			125 780		Anti-PD-1 alive 2.2 years
12	Primary*	Yes/no	43 591	98 574	126	18 382	56 068	205	8299	36 310	338	Alive 2 years

*These patients received anti-PD-1 within 30 days of PVRSIPO, therefore, confirmation of disease progression on anti-PD-1 prior to study enrolment at 4 weeks did not occur. Patients in gray are responders to lerapolturev.